Custom Bremelanotide/PT141 CAS 189691-06-3 - China Suppliers & Factory for Melanocortin Receptor Agonist Quotes, Service
Bremelanotide is a synthetic melanocortin receptor agonist that was initially developed as a tanning agent. It is a metabolite of MT-I and has been identified for its potential to enhance sexual function. Unlike traditional erectile dysfunction medications that primarily address hemodynamic issues, Bremelanotide works by directly influencing melanocortin receptors in the central nervous system, especially in the hypothalamus. This innovative approach means it is neither a hormone nor reliant on the nitric oxide pathway, making it a unique therapeutic option for both men and women. Administered via subcutaneous injection, this drug is becoming increasingly sought after by manufacturers and healthcare providers alike. As a leading product from our factory in China, we connect businesses with top-tier suppliers to meet their demand for effective sexual wellness solutions
Bremelanotide is a synthetic melanocortin receptor agonist. Originally developed as a tanning agent, it is a metabolite of the compound MT-I and was later found to promote sexual function. Unlike most medications for erectile dysfunction in men targeting hemodynamic issues, it regulates libido by acting directly on melanocortin receptors in the central nervous system, particularly the hypothalamus. Its uniqueness lies in the fact that it is neither a hormone nor a nitric oxide pathway-based drug, and it has potential therapeutic effects in both men and women. The drug is administered via subcutaneous injection.
Therapeutic Areas
Approved
Female sexual interest/arousal disorders: In 2019, its branded drug Vyleesi was approved by the U.S. FDA for the treatment of acquired and generalized sexual interest/arousal disorders in premenopausal women.
Main Research and Potential Application Areas
Male erectile dysfunction: Especially suitable for male patients who do not respond to or cannot use such drugs (e.g., due to contraindications to nitrates). Its mechanism of action is independent of the nitric oxide pathway.
Low libido in men: A potential treatment for improving libido.
Female sexual dysfunction: In addition to the approved indications, its efficacy for other types of female sexual dysfunction is still under investigation.
Sexual dysfunction caused by antidepressants: A possible coping strategy for sexual dysfunction side effects caused by SSRIs.
Outlook & Development
Market Positioning and Prospects
Its core potential lies in meeting unmet medical needs, providing an important alternative for patients who are unresponsive to or intolerant of existing first-line therapies (such as PDE5 inhibitors). In the field of female sexual dysfunction, it is one of the few approved drugs, giving it a first-mover advantage.
Its mechanism of regulating libido by acting on the central nervous system gives it a theoretical advantage in treating the core problem of "lack of sexual interest".
Future development may depend on expanding indications (especially approval for male indications), optimizing administration methods (such as developing more convenient nasal sprays), and increasing public and medical awareness and willingness to seek treatment for related diseases.
Development and Challenges
Key challenges include: side effects (the most common being nausea and flushing, as well as the risk of increased blood pressure, which limits use for some patients), route of administration (requiring subcutaneous injection, which is less convenient than oral medications), and market acceptance and education (underdiagnosis and stigma still exist in the field of sexual dysfunction).
Development had previously focused on intranasal formulations, but related research has been interrupted or progressed slowly. Currently, the developers are primarily focused on commercializing the product in the market for its approved female indications and exploring potential applications for other central nervous system-related diseases.
Frequently Asked Questions (FAQ)
What is Bremelanotide and how does it work?
Bremelanotide is a synthetic melanocortin receptor agonist. Unlike typical erectile dysfunction medications that target blood flow, it regulates libido by acting directly on the central nervous system, specifically the hypothalamus.
Is Bremelanotide a hormone?
No, its uniqueness lies in the fact that it is neither a hormone nor a nitric oxide pathway-based drug.
How is Bremelanotide administered?
Currently, the drug is administered via subcutaneous injection. While intranasal formulations were explored, their development has progressed slowly.
What are the approved uses for this medication?
In 2019, its branded drug Vyleesi was approved by the U.S. FDA specifically for the treatment of acquired and generalized sexual interest/arousal disorders in premenopausal women.
Can men use Bremelanotide?
It has potential therapeutic effects for men, especially for male erectile dysfunction (for those who cannot use standard drugs like nitrates) and low libido. However, these applications are still under main research.
What are the common side effects and challenges?
The most common side effects include nausea and flushing, along with a risk of increased blood pressure. Other challenges include the inconvenience of subcutaneous injections and market stigma surrounding sexual dysfunction.
